Registers net profit of Rs 11.73 crore showing a growth of 16 per cent
Hester Biosciences announced the financial results of Q2 and H1 of FY 2021-22. In Q2 FY 22, the company’s revenue from operations was at Rs 56.59 crore showing a growth of 6 per cent, net profit at Rs 11.73 crore showing a growth of 16 per cent.
During H1 FY 22, revenue from operations was at Rs 115.10 crore and net profit was at Rs 24.01 crore. Sales for Q2 FY22 and Q1 FY22 grew by 6 per cent and 50 per cent with overall H1 FY22 being higher by 24 per cent as compared to corresponding periods. Overall, the sales of vaccines have registered a growth of 13 per cent in Q2 FY22 and 26 per cent in H1 FY22, and the sales of health products have registered a growth of 31 products in Q2 FY22 and 53 per cent in H1FY22. Domestic sales have registered a growth of 21 per cent in Q2 FY22 and 38 per cent in H1FY22. There is a marginal decrease in export sales in Q2 and H1 FY22. Export orders are affected due to restricted cargo movements globally.
The board of the company has been expanded by taking in two additional directors Priya Gandhi, Executive Director and Ameet Desai, Independent Director.
